{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:09:13Z","timestamp":1795018153975,"version":"4.10.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer screening participation is suboptimal in most settings. We assessed whether human papillomavirus (HPV) self-sampling may increase screening participation among long-term non-attenders in Norway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A pragmatic randomised controlled trial with participation as the primary outcome was initiated in the national cervical screening programme in March 2019. A random sample of 6000 women aged 35\u201369 years who had not attended screening for at least 10 years were randomised 1:1:1 to receive either (i) a reminder to attend regular screening (control), (ii) an offer to order a self-sampling kit (opt-in) for HPV testing or (iii) a self-sampling kit unsolicited (send-to-all) for HPV testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Total participation was 4.8%, 17.0% and 27.7% among control, opt-in and send-to-all (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001; participation difference (%) send-to-all vs. control: 22.9 (95%CI: 20.7, 25.2); opt-in vs. control: 12.3 (95%CI: 10.3, 14.2); send-to-all vs. opt-in: 10.7 (95% CI: 8.0, 13.3)). High-risk HPV was detected in 11.5% of self-samples and 9.2% of clinician-collected samples (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.40). Most women (92.5%) who returned a positive self-sample attended the clinic for triage testing. Of the 933 women screened, 33 (3.5%) had CIN2\u2009+\u2009(1.1%, 3.7%, 3.8% among control, opt-in, and send-to-all, respectively), and 11 (1.2%) had cervical cancer (0%, 1.2%, 1.3% among control, opt-in, send-to-all, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Opt-in and send-to-all self-sampling increased screening participation among long-term, higher-risk non-attenders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov NCT03873376.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-022-01954-9","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T23:40:52Z","timestamp":1661211652000},"page":"1816-1826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8981-5374","authenticated-orcid":false,"given":"Gunvor","family":"Aasb\u00f8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameli","family":"Trop\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-4855","authenticated-orcid":false,"given":"Mari","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Kraus","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Baasland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grete Alrek","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane Cecilie","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit Halonen","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro Kummeneje","family":"Presthus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Undem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9096-5257","authenticated-orcid":false,"given":"Tone","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo T.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"1954_CR1","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/ijc.29541","volume":"137","author":"S L\u00f6nnberg","year":"2015","unstructured":"L\u00f6nnberg S, Hansen BT, Haldorsen T, Campbell S, Schee K, Nyg\u00e5rd M. Cervical cancer prevented by screening: Long-term incidence trends by morphology in Norway. Int J Cancer. 2015;137:1758\u201364.","journal-title":"Int J Cancer"},{"key":"1954_CR2","first-page":"682","volume":"128","author":"T Haldorsen","year":"2008","unstructured":"Haldorsen T, Skare GB, Steen R, Thoresen SO. Livmorhalskreft etter ti \u00e5rs offentlig koordinert screening. [Cervical cancer after 10 years of nationally coordinated screening]. Tidskr NorLegefor. 2008;128:682\u20135.","journal-title":"Tidskr NorLegefor"},{"key":"1954_CR3","unstructured":"Cancer Registry of Norway. Annual rapport 2019, Screening Activity and Results from the National Cervical Cancer Screening Programme, [\u00c5rsrapport 2019, Screeningaktivitet og resultater fra Livmorhalsprogrammet]. 2020. https:\/\/www.kreftregisteret.no\/globalassets\/livmorhalsprogrammet\/rapporter\/arsrapport-lp\/arsrapport-livmorhalsprogrammet-2019v2_sept2021.pdf [Accessed 10 Feb, 2022]."},{"key":"1954_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jnci\/djn099","volume":"100","author":"B Andrae","year":"2008","unstructured":"Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/eurpub\/ckx073","volume":"27","author":"K Pedersen","year":"2017","unstructured":"Pedersen K, Burger EA, Campbell S, Nyg\u00e5rd M, Aas E, L\u00f6nnberg S. Advancing the evaluation of cervical cancer screening: development and application of a longitudinal adherence metric. Eur J Public Health. 2017;27:1089\u201394.","journal-title":"Eur J Public Health"},{"key":"1954_CR6","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/ijc.32374","volume":"145","author":"KM Elfstr\u00f6m","year":"2019","unstructured":"Elfstr\u00f6m KM, Sundstr\u00f6m K, Andersson S, Bzhalava Z, Thor AC, Czoul Z, et al. Increasing participation in cervical screening by targeting long-term nonattenders: randomized health services study. Int J Cancer. 2019;145:3033\u20139.","journal-title":"Int J Cancer"},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/jfprhc-2012-100378","volume":"38","author":"L Cadman","year":"2012","unstructured":"Cadman L, Waller J, Ashdown-Barr L, Szarewski A. Barriers to cervical screening in women who have experienced sexual abuse: an exploratory study. J Fam Plan Reprod Health Care. 2012;38:214\u201320.","journal-title":"J Fam Plan Reprod Health Care"},{"key":"1954_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/pon.4126","volume":"26","author":"AJ Chorley","year":"2017","unstructured":"Chorley AJ, Marlow LAV, Forster AS, Haddrell JB, Waller J. Experiences of cervical screening and barriers to participation in the context of an organised programme: a systematic review and thematic synthesis. Psycho-Oncol. 2017;26:161\u201372.","journal-title":"Psycho-Oncol"},{"key":"1954_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ypmed.2016.11.018","volume":"94","author":"MK Leinonen","year":"2017","unstructured":"Leinonen MK, Campbell S, Klungs\u00f8yr O, L\u00f6nnberg S, Hansen BT, Nyg\u00e5rd M. Personal and provider level factors influence participation to cervical cancer screening: a retrospective register-based study of 1.3 million women in Norway. Prev Med. 2017;94:31\u20139.","journal-title":"Prev Med"},{"key":"1954_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-264","volume":"11","author":"BT Hansen","year":"2011","unstructured":"Hansen BT, Hukkelberg SS, Haldorsen T, Eriksen T, Skare GB, Nygard M. Factors associated with non-attendance, opportunistic attendance and reminded attendance to cervical screening in an organized screening program: a cross-sectional study of 12,058 Norwegian women. BMC Public Health. 2011;11:264.","journal-title":"BMC Public Health"},{"key":"1954_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/eurpub\/ckx093","volume":"27","author":"MK Leinonen","year":"2017","unstructured":"Leinonen MK, Campbell S, Ursin G, Trope A, Nygard M. Barriers to cervical cancer screening faced by immigrants: a registry-based study of 1.4 million women in Norway. Eur J Public Health. 2017;27:873\u20139.","journal-title":"Eur J Public Health"},{"key":"1954_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12\u20139.","journal-title":"J Pathol"},{"key":"1954_CR13","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3390\/v7072802","volume":"7","author":"N Egawa","year":"2015","unstructured":"Egawa N, Egawa K, Griffin H, Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 2015;7:3863\u201390.","journal-title":"Viruses"},{"key":"1954_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","volume":"393","author":"PA Cohen","year":"2019","unstructured":"Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393:169\u201382.","journal-title":"Lancet"},{"key":"1954_CR15","doi-asserted-by":"publisher","first-page":"k4823","DOI":"10.1136\/bmj.k4823","volume":"363","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.","journal-title":"BMJ"},{"key":"1954_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S1470-2045(13)70570-9","volume":"15","author":"M Arbyn","year":"2014","unstructured":"Arbyn M, Verdoodt F, Snijders PJF, Verhoef VMJ, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15:172\u201383.","journal-title":"Lancet Oncol"},{"key":"1954_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/sextrans-2016-052609","volume":"93","author":"EJ Nelson","year":"2017","unstructured":"Nelson EJ, Maynard BR, Loux T, Fatla J, Gordon R, Arnold LD. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect. 2017;93:56\u201361.","journal-title":"Sex Transm Infect"},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"e0151978","DOI":"10.1371\/journal.pone.0151978","volume":"11","author":"E Enerly","year":"2016","unstructured":"Enerly E, Bonde J, Schee K, Pedersen H, Lonnberg S, Nygard M. Self-sampling for human papillomavirus testing among non-attenders increases attendance to the Norwegian cervical cancer screening programme. PLoS ONE. 2016;11:e0151978.","journal-title":"PLoS ONE"},{"key":"1954_CR19","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ijc.28545","volume":"134","author":"G Broberg","year":"2014","unstructured":"Broberg G, Gyrd-Hansen D, Jonasson JM, Ryd ML, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2014;134:2223\u201330.","journal-title":"Int J Cancer"},{"key":"1954_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.30031","volume":"139","author":"F Sultana","year":"2016","unstructured":"Sultana F, English DR, Simpson JA, Drennan KT, Mullins R, Brotherton JM, et al. Home-based HPV self-sampling improves participation by never-screened and under-screened women: results from a large randomized trial (iPap) in Australia. Int J Cancer. 2016;139:281\u201390.","journal-title":"Int J Cancer."},{"key":"1954_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/ijc.31391","volume":"143","author":"E Kellen","year":"2018","unstructured":"Kellen E, Benoy I, Vanden Broeck D, Martens P, Bogers JP, Haelens A, et al. A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program. Int J Cancer. 2018;143:861\u20138.","journal-title":"Int J Cancer"},{"key":"1954_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4165-4","volume":"18","author":"M Tranberg","year":"2018","unstructured":"Tranberg M, Bech BH, Blaakaer J, Jensen JS, Svanholm H, Andersen B. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial. BMC Cancer. 2018;18:273.","journal-title":"BMC Cancer"},{"key":"1954_CR23","unstructured":"Norwegian Directorate of Health. National Guidelines of Gynaecological Cancer [Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft]. 3. ed. 2021. https:\/\/www.helsedirektoratet.no\/retningslinjer\/gynekologisk-kreft-handlingsprogram [Accessed 8 Feb, 2022]."},{"key":"1954_CR24","unstructured":"Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. In: WHO classification of tumours, 3rd edn. 4. Lyon: IARC Press; 2003."},{"key":"1954_CR25","doi-asserted-by":"publisher","first-page":"k499","DOI":"10.1136\/bmj.k499","volume":"360","author":"K Tainio","year":"2018","unstructured":"Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Hern\u00e1ndes JC, Glazer-Livson S, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.","journal-title":"BMJ"},{"key":"1954_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.ejca.2015.07.006","volume":"51","author":"F Verdoodt","year":"2015","unstructured":"Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJ, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015;51:2375\u201385.","journal-title":"Eur J Cancer"},{"key":"1954_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0969141314558785","volume":"22","author":"L Cadman","year":"2015","unstructured":"Cadman L, Wilkes S, Mansour D, Austin J, Ashdown-Barr L, Edwards R, et al. A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening. J Med Screen. 2015;22:28\u201337.","journal-title":"J Med Screen"},{"key":"1954_CR28","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/ijc.30647","volume":"140","author":"JU Lam","year":"2017","unstructured":"Lam JU, Rebolj M, Ejegod DM, Pedersen H, Rygaard C, Lynge E, et al. Human papillomavirus self-sampling for screening nonattenders: opt-in pilot implementation with electronic communication platforms. Int J Cancer. 2017;140:2212\u20139.","journal-title":"Int J Cancer"},{"key":"1954_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/sj.bjc.6605194","volume":"101","author":"K Sanner","year":"2009","unstructured":"Sanner K, Wikstr\u00f6m I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer. 2009;101:871\u20134.","journal-title":"Br J Cancer"},{"key":"1954_CR30","doi-asserted-by":"publisher","first-page":"e029505","DOI":"10.1136\/bmjopen-2019-029505","volume":"9","author":"G Aasb\u00f8","year":"2019","unstructured":"Aasb\u00f8 G, Solbr\u00e6kke KN, Waller J, Trop\u00e9 A, Nyg\u00e5rd M, Hansen BT. Perspectives of non-attenders for cervical cancer screening in Norway: a qualitative focus group study. BMJ Open. 2019;9:e029505.","journal-title":"BMJ Open"},{"key":"1954_CR31","doi-asserted-by":"publisher","first-page":"356.e1","DOI":"10.1016\/j.ajog.2007.07.049","volume":"197","author":"PE Castle","year":"2007","unstructured":"Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356.e1\u2013e3566.","journal-title":"Am J Obstet Gynecol"},{"key":"1954_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/bjc.2011.351","volume":"105","author":"M Arbyn","year":"2011","unstructured":"Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br J Cancer. 2011;105:877\u201380.","journal-title":"Br J Cancer"},{"key":"1954_CR33","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41416-020-0790-1","volume":"122","author":"D Hashim","year":"2020","unstructured":"Hashim D, Enges\u00e6ter B, Skare GB, Castle PE, Bj\u00f8rge T, Trop\u00e9 A, et al. Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. Br J Cancer. 2020;122:1715\u201323.","journal-title":"Br J Cancer"},{"key":"1954_CR34","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41416-020-0787-9","volume":"122","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Rezhake R, Yuill S, Canfell K. Triage of HPV-positive women in Norway using cytology, HPV16\/18 genotyping and HPV persistence. Br J Cancer. 2020;122:1577\u20139.","journal-title":"Br J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01954-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01954-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01954-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T19:03:45Z","timestamp":1667934225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01954-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,11,9]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01954-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.28.22276756","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"10 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Castle has received HPV tests and assays for research at a reduced or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Study approval was obtained from the Regional Committees for Medical and Health Research Ethics (2019\/111) and Oslo University Hospital\u2019s Data Protection Officer (18\/14056). A statement regarding the processing of personal data was also obtained from the Data Protection Officer at Akershus University Hospital. For women in self-sampling arms, the invitation included information that by returning the self-sample, they consented to the subsequent procedures described in the invitation letter. All invited women, including those in the control arm, were informed that they could withdraw from the study at any time. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}